Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05547321
Title Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors.
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Oncomatryx Biopharma S.L.
Indications

leiomyosarcoma

head and neck squamous cell carcinoma

ovary serous adenocarcinoma

breast cancer

Advanced Solid Tumor

pancreatic ductal adenocarcinoma

colorectal cancer

stomach cancer

lung non-small cell carcinoma

esophageal cancer

Therapies

OMTX705 + Pembrolizumab

OMTX705

Age Groups: senior | adult
Covered Countries USA | ESP


No variant requirements are available.